Even in the present times, there remains a role for augmentation cystoplasty, although its use has become less common due to other less invasive procedures such as intravesical injection of botulinum toxin A and neuromodulation. Ileocystoplasty is the most commonly performed bladder augmentation procedure because of the reconstructive urologist's familiarity with ileum and the ileum's ability to easily reach to the pelvis.
Introduction
Augmentation cystoplasty (AC) has been traditionally indicated in the surgical management of a small-capacity, high-pressure, poorly compliant, or overactive bladder. AC is performed so as to provide urinary storage, protect the upper urinary tract, preserve the renal function, provide continence and resistance to infection, and offer a convenient method of voluntary and complete emptying. [1] Newer means of interventions such as drugs, intravesical injection of botulinum toxin A, are reducing, but not completely eliminating the need for AC. In most Western countries, the overall number of bladder augmentation procedures (ileocystoplasty, colocystoplasty, caecocystoplasty, and specified and unspecified enlargement of the bladder) has shown an overall downward trend over the last decade. [2] Augmentation ileocystoplasty was first described in humans by von Mikulicz in 1889, [3] and the technique was popularized by Couvelaire, [4] as a treatment for small contracted tuberculous bladders. The introduction of clean intermittent self-catheterization (CISC) further widened the use of AC following publications by Bramble. [5] Ileocystoplasty is the most commonly performed bladder augmentation procedure, though several other different types of bowel have been used successfully, including the cecum and ascending and sigmoid colon. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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Indications and Contraindications
Indications for augmentation ileocystoplasty include overactive bladder, congenital bladder anomalies such as bladder and cloacal exstrophy, [6, 7] posterior urethral valves, [8] and epispadias. [6, 7] Other indications include patients with end-stage renal failure with high-pressure reflux and a need to prevent graft failure. [9] Tuberculosis, schistosomiasis, and pelvic radiotherapy cause fibrosis of the wall of the bladder, resulting in a low-volume, high-pressure, and poorly compliant bladder. These bladders also form an indication for augmentation.
Contraindications for augmentation include intrinsic bowel disease (Crohn's disease), short or abnormal bowel. Reduced manual dexterity or cognitive function leading to an inability to perform CISC is another relative contraindication. Significant renal impairment is a controversial relative contraindication.
The reconstructive urologist's familiarity with ileum and the ileum's ability to easily reach to the pelvis have made ileocystoplasty the most common type of AC. Hyperchloremic metabolic acidosis is known to occur after using ileum or colon for bladder substitution, however the use of ileum results in less significant metabolic disturbances.
Surgical Technique
A standard midline laparotomy incision is most often used, though a lower abdominal transverse incision can also be used. [10] The chosen ileal segment [ Figure 1a and b] should be based 15-20 cm away from the ileocecal valve to preserve the absorptive function of the terminal ileum. It should be between 15 and 40 cm long (usually about 25 cm), depending on the patient's age and the desired augmentation of bladder volume [ Figure 2a and b]. A slightly longer segment is preferable to one that is too short. The mobility of the segment of the ileum (intestine) is tested before dividing the ileum so as to ensure that it will reach the bladder without tension. A vascular arcade is created within the mesentery of the isolated ileal segment. After re-establishing the continuity of ileal segments, mesenteric defects should always be closed so as to prevent internal hernia formation. Small bowel should not be divided more than 8 cm from an arcade artery so as to prevent ischemic necrosis. The abdomen should be packed and draped carefully to prevent contamination of the surgical field with ileal contents. Ileal segments should be irrigated thoroughly to remove gastrointestinal contents.
Ileal segments should be detubularized by incising them with a cautery on the antimesenteric side so as to create a rectangular surface and to minimize forceful contractions in the augmented bladder [ Figure 3a and b]. Forming the intestinal segment into a semi-spherical shape gives the augmented bladder maximal capacity and compliance. A wide anastomosis between the segment and the native bladder is important for optimal volume and drainage. A vesicointestinal anastomosis is then performed in 1-2 layers with a 2-0 absorbable suture. A suprapubic tube should be placed through the opened bladder and brought out through a separate skin incision. A drain is placed near the bladder as an indicator for urinary leakage.
Early Complications
Wound infection (5%-6.4%), small bowel obstruction (3%-5.7%), and bleeding requiring reoperation (0%-3%) are some of the early complications that are seen. [1] Regular CISC is needed in 6%-39% of patients with idiopathic detrusor overactivity (IDO) and ≈ 60% of patients with neurogenic detrusor overactivity. [1] The mortality rate from AC is reported to be 0%-2.7%. [1] 
Long-term Complications
Failure
Failure of augmentation to completely resolve the underlying lower urinary tract symptoms and need for revision surgery has been reported in 5%-42% of patients. [11, 12] Outcomes are worse in patients with IDO with long-term success in as few as 53%-58%. [12, 13] 
Metabolic disturbances
The incidence of hyperchloremic acidosis requiring oral bicarbonates has been reported at 16%. [14] Ileocystoplasty leads to hyperchloremic acidosis due to reabsorption of urinary ammonia and ammonium chloride and, to a lesser extent, secretion of bicarbonate by the bowel segment, resulting in a biochemically detectable acid-base and electrolyte disturbance in virtually all patients, but clinically important in very few.
Renal function
Renal function deterioration has been reported after ileocystoplasty, and appears to be related to baseline renal function and associated factors of detrusor fibrosis and raised detrusor leak-point pressures. [15] About 15% of patients with a creatinine clearance of at least 15 mL/min had deterioration, whereas only 4.1% of patients with a creatinine clearance ≥40 mL/min deteriorated. [1] 
Mucus secretion
The average mucus secretion following ileocystoplasty is about 35-40 g. The mucus secretion does not reduce substantially inspite of a time-related villous atrophy of the intestinal patch mucosa. Mucus accumulation can predispose to urinary tract infection (UTI), stone formation, bladder outlet obstruction, and can occasionally contribute to bladder perforation. Oral ranitidine has been shown to reduce the amount of mucus produced, [16] and acetylcysteine washouts help to dissolve excess mucus. [17, 18] Other long-term complications include persistent asymptomatic bacteriuria with mixed organisms. The incidence of significant UTI has been reported to be around 4%-43%. [19, 20] UTI is associated with elevated levels of urinary nitrosamine, which has been implicated in the development of cancer in bladder augmentation. [1] Antibiotic prophylaxis has been shown to reduce the nitrosamine levels. [1] Formation of urinary stones, development of vesicoureteric reflux, and spontaneous perforation of the bladder are some other noteworthy long-term complications.
